PIPELINE

Clinical Need

logo Vaxdyn blanco-verde

Preventing the next global health crisis

All medical and economic implications of how humanity is getting into a post-antibiotic era were well summarized in the review “Alternatives to antibiotics – a pipeline portfolio review”*, reporting results from the “The Review on Antimicrobial Resistance”, a estudy commissioned by the UK goverment and sponsored by the Wellcome Trust. In 2022, the Global Research on Antimicrobial Resistance (GRAM) paper**, called for immediate action, giving figures to understand the magnitude of the problem.

* Czaplewski et al. (2016), Lancet Infect Dis. 16(2):239-51

** Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis, The Lancet. DOI:http://doi.org/10.1016/S0140-6736(12)02724-0

AMR – A silent Pandemic

The Anti-Microbial Resistance (AMR) global health crisis is already affecting more than 100M people annually, causing 1.27 million deaths in 2019. AMR has been confirmed as a leading cause of death around the world. By 2050 we can expect 10 million deaths due to infections resistant to antibiotics if no immediate actions are taken. The current impact in the global economy suspasses USD 40 billion per year. Among the killers, 6 antibiotic-resistant bacteria account for 73% of deaths attributable to bacterial AMR: Acinetobacter baumannii, Klebsiella pneumoniae, Pseudomonas aeruginosa, Escherichia coli, Staphylococcus aureus, and Streptococcus pneumoniae.

Vaccination is one of the actions called

Preventing infections through vaccinations is paramount for reducing the need of antibiotics, and for the immediate decrease of the burden of AMR in certain highly affected populations. The lead vaccine candidate of Vaxdyn aims to prevent infections from 3 out of the 6 major killers: A. baumannii, K. pneumoniae, and P. aeruginosa.

Preventing is a significant part of the solution within an OneHealth approach. While AMR occurs naturally, its rate and spread of occurrence has been accelerated by the inappropriate and overuse of antibiotics in both people and animals.

The World Health Organization (WHO) and Center for Diseases Control (CDC) of the USA published a list of the most worrisome bacteria, mainly because their capacity of resistance to all or almost all available antibiotics.

Bacteria are part of the human body. We are naturally colonized by bacteria, which play a role in our immune system and metabolism. Infections occur when our immune system cannot cope with the microbial population in our body and there is spread and infection of tissues in lungs, urinary tract or soft tissues. If these infections cannot be stopped on-time with antibiotics, the result is a life-threatening systemic infection of the body.

The pathogens colonizing people are increasingly AMR pathogens, which means that once the infection is established, it is very difficult to stop it with available antibiotics.

Vaxdyn's view is to give enhanced and refocused immunity against the most worrisome AMR pathogens to the populations at risk before the infection is produced, preventing the infection episode without the need of antibiotics. In parallel, the immunity raised in these highly susceptible people will decrease the evolution and spread of AMR pathogens.

There is no vaccine available or in the clinical phase of development against the most urgent threats from the list of the WHO (Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacteriaceae like Klebsiella pneumoniae)


Preventive vaccines for high-risk populations are urgently needed

Vaccination will decrease the incidence of antimicrobial resistance (AMR) infections in highly susceptible populations, like people with chronic lung disease, cancer patients, subjected to dialysis, patients with chronic liver damage, with diabetes, in the waiting list for solid-organ transplantation, women with recurrent urinary-tract infections, and neonates, especially in low and middle-income countries. All these populations are prone to develop recurrent infections by opportunistic bacterial pathogens.

Neonatal deaths. Klebsiella pneumoniae and Acinetobacter baumannii are within the most frequent causes of neonatal deaths in the world. Within the countries surveyed by CHAMPS (www.champshelaths.com), both bacteria are the leading causes of neonatal deaths, accounting together for 70% of infectious neonatal deaths.

The primary target population in need of the lead vaccine candidate of Vaxdyn are the population affected by Chronic Obstructive Pulmonary Disease (COPD). COPD is currently the third biggest killer disease, according to WHO. There are 36 million people affected by COPD only in USA+EU (increment of 120.000/year). The prevalence of Pseudomonas aeruginosa or Klebsiella pneumoniae as causative agents of infections in this population is currently 8-15% (and rising).


The subgroup patient with recurrent severe acute exacerbations must be treated with mechanical ventilation and intravenous antibiotics, raising the risk of development of pneumonia caused by multi-drug resistant P. aeruginosa, K. pneumoniae, and/or A. baumannii, with 50% mortality rate associated. Once approved, the use of a vaccine candidate against these pathogens can be extended to other high-risk populations and serve for ameliorating and content the AMR crisis all over the world. In addition to alleviating the crisis in populations of high-income countries, Vaxdyn and its funders are committed to tackle the burden of the AMR crisis in low and middle income countries, where the situation is specially grave.

CONTACT

Vaxdyn

Supported by

CONTACT US


Vaxdyn logo
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.